By Andrea Figueras


Roche said it obtained positive results for its investigational treatment, inavolisib, as a first-line treatment for people with breast cancer.

The drug, which combines palbociclib and fulvestrant, reduced the risk of disease worsening or death by 57% compared to palbociclib and fulvestrant alone, the Swiss pharmaceutical company said on Friday.

The treatment is currently being investigated in Phase III in people with PIK3CA-mutated locally advanced or metastatic breast cancer, the company said.

"The benefit was consistent across subgroups," Roche said, noting that overall survival data were immature at this time, but that it has observed a clear positive trend.

The clinically meaningful benefit observed with the inavolisib combination builds on our commitment to improve outcomes across all types of breast cancer, Chief Medical Officer and Head of Global Product Development Levi Garraway said.

Roche will submit data from the study to authorities, but didn't disclose a date for the release of the potential treatment option.


Write to Andrea Figueras at


(END) Dow Jones Newswires

December 08, 2023 12:23 ET (17:23 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.